RxDoctor Payments DataLook up a doctor →

Kai Yang, MD

Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1093851321

Payments from drug & device makers

$8,224in general payments, 2019–2025

Across 459 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$929
  • Lilly USA, LLC$726
  • AstraZeneca$665
  • AbbVie$565
  • Sanofi-aventis U.S. LLC$423
  • plus $4K from 38 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk92$1,245
Amgen(2 entities)52$929
Lilly USA, LLC43$726
AstraZeneca30$665
AbbVie37$565
Sanofi-aventis U.S. LLC28$423
Abbott21$370
Insulet Corporation17$364
Boehringer Ingelheim11$290
Amarin Pharma, Inc.18$283
Corcept Therapeutics7$247
Ipsen Biopharmaceuticals, Inc13$208
Bayer4$196
Mannkind Corporation8$192
Amneal Pharmaceuticals LLC8$155
Radius Health, Inc.6$110
Merck7$105
Medtronic(2 entities)5$105
Dexcom, Inc.4$100
Lifescan, Inc.5$82
Ultragenyx Pharmaceutical Inc.3$77
IBSA Pharma Inc.4$75
Sequel Med Tech, LLC3$65
Siemens Medical Solutions USA, Inc.1$62
Shire North American Group Inc3$54
Aytu Biopharma, Inc.3$47
Tandem Diabetes Care, Inc.2$43
Embecta Corp.1$37
Currax Pharmaceuticals LLC2$37
Zealand Pharma US, Inc.2$35
Pfizer3$35
Ascensia Diabetes Care US Inc.2$35
BD2$34
Companion Medical, Inc.2$33
Neurocrine Biosciences, Inc.1$31
Almatica Pharma LLC1$26
Senseonics, Incorporated1$22
Alfasigma USA, Inc.1$21
Acella Pharmaceuticals, LLC1$19
Johnson & Johnson1$19
Acerus Pharmaceuticals Corporation1$18
BETA Bionics, Inc.1$15
Xeris Pharmaceuticals, Inc.1$13
Endo Pharmaceuticals Inc.1$12

How this compares

$8,224 in reported general payments places this provider in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024
$69,879
Medicare patients
261
Services billed
1,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in New Haven

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →